Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05558007
Other study ID # BZ371CLI004
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date November 22, 2023
Est. completion date September 2024

Study information

Verified date March 2024
Source Biozeus Biopharmaceutical S.A.
Contact Camilla NR Trindade, PhD
Phone +55(21)2523-9089
Email camilla.nunes@biozeus.com.br
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine efficacy, safety and tolerabiltiy of topically applied BZ371A in patients that experienced RP, in combination with daily tadalafil compared to placebo.


Description:

Prostate cancer remains one of the most prevalent cancer in men. For its treatment, recent technological advances demonstrate that the most effective treatment is the Radical Prostatectomy (RP) procedure. However, although curative for Prostate Cancer, can result in damage to the cavernosal nerves. The cavernosal autonomic nerves travel posterolaterally to the prostate to enter the penis and regulate blood flow and hence erection. Thus, damage caused by RP will affect NO tissue release and blood flow regulation, causing erectile dysfunction. BZ371A has the ability to restore local blood flow regulation by a new and innovative mechanism of action and, therefore, has potential to be a supportive therapy for RP patients (restoring the erectile function). Thus, this study aims to evaluate efficacy, safety and tolerabilty of BZ371A on the recovery of erectile function of patients that were underwent Radical Prostatectomy.


Recruitment information / eligibility

Status Recruiting
Enrollment 72
Est. completion date September 2024
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender Male
Age group 40 Years to 65 Years
Eligibility Inclusion Criteria: 1. Men between the ages of 40 and 65 years; 2. Exclusive heterosexual men, regardless of race or social class. 3. RP due to prostate cancer without metastasis; 4. RP performed less than 60 days before the screening visit; 5. Erectile function prior to normal RP, defined as IIEF questionnaire with more than 22 points in domain A; 6. Stable sexual partner (more than 2 months prior to RP), and intention to maintain the relationship during the study. 7. Continuous use of 5mg Tadalafil from the 30th up to the 60th day after RP. Exclusion Criteria: 1. Prostate cancer in TNM stage classified as T3 or T4. 2. Perineal and/or open RP; 3. Necessity of other therapy for prostate cancer than RP, including radiation therapy or hormone therapy; 4. Uncontrolled diabetes at screening visit (HbA1C > 10%); 5. Prior spinal cord injury with lower limb paralysis; 6. Current male hormone use, or hypogonadism, defined by total testosterone below 8 nmol/L (2300 pg/mL) or total testosterone between 8 and 11 nmol/L (2300 and 3170 pg/mL) and free testosterone < 220 pmol/L (< 64 ng/dL); 7. Patients with current depression, characterized by use or need for use of antidepressants. 8. Presence of genital lesions (such as severe penile fibrosis or Peyronie's disease) or active sexually transmitted disease (STD) (such as herpes, gonorrhea, candidiasis, HPV, and others) that impair analysis of local adverse effects on the genitalia; 9. Use of topical medications in the genital region that may interfere in the IP evaluation, as well as in its absorption or drug interaction; 10. Possession of penile prosthesis; 11. History of symptomatic hypotension, or diseases that increase the risk of symptomatic hypotension, such as patient with heart diseases (including history of angina and/or heart failure) and nephropathies; 12. Current use of nitrates, such as propatilnitrate (Sustrate®), isosorbide (Monocordil®, Cincordil®, Isordil®), nitroglycerin (Nitradisc®, Nitroderm TTS®, Nitronal®, Tridil®) and isosorbitol dinitrate (Isocord®);ketoconazole; ritonavir; and rifampicin. 13. Findings on ECG and/or laboratory tests that, in the Investigator's criteria, are considered significant and offer risk to the research volunteer's participation or may hinder the study analyses; 14. BP outside the limits considered safe: SBP below 90 mmHg or above 170 mmHg; or DBP below 50 mmHg or above 100 mmHg, except situations such as "white coat syndrome"; 15. Diseases that can cause priapism, such as sickle cell anemia, multiple myeloma, or leukemia; 16. Histroy of priapism, defined as painful erection from up to 6 hours. 17. Current relevant diarrhea, defined as duration over four weeks, association with abdominal pain or dysabsortive syndrome, or presence of mucus, pus, or blood in the stool; 18. Known hypersensitivity to tadalafil and/or BZ371A; 19. History of symptomatic Lactose intolorence such as: the necessity of enzymatic treatment, abdominal distension or diarrhea when ingesting products or supplements with lactose; 20. Low adhsesion to 5mg Tadalafil use, characterized by the use of <80% of the pills between the 30th and 60th day post PR;. 21. Pregnant or lacting partner. 22. Partner in childbearing age which does not accept to get exposed to the treatment 23. Any disease, condition or physical finding that the Investigator considers significant and that increases the risk of the research subject's participation or may interfere with the results, including severe debilitating illness, presence of cancer other than prostate cancer, severe mental illness persistent medication abuse;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tadalafil 5mg
Daily oral administration of tadalafil 5mg
BZ371A
Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL
Oral Placebo
Oral administration of a placebo pill
Topical Placebo
Topical application of 1.5 mL of placebo

Locations

Country Name City State
Brazil Hospital Urológica Belo Horizonte

Sponsors (1)

Lead Sponsor Collaborator
Biozeus Biopharmaceutical S.A.

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Assisted Erectile Function Measurement of the ability to to have an erection that allows sexual intercourse, under use of medication. This will be assessed by using the IIEF questionnaire, domain A (erectile function section) (IIEF-EF). From up to 30 days before Baseline, Baseline, 30 days, 60 days
Secondary Change in successful vaginal intercourse rate Rate of successful vaginal intercourse will be assessed through question 3 of the SEP (Sexual Encouter Profile) questionnaire. From up to 30 days before Baseline, Baseline, 30 days, 60 days
Secondary Change in quality of sexual intercourse Quality of sexual intercourse, through the EDITS questionnaire (Erectile Dysfunction Inventory of Treatment Satisfaction); 30 days, 60 days
Secondary Change in penile extension Penile extension, measured with a ruler. Baseline, 30 days, 60 days
Secondary Penile Blood flow increase Increased blood flow, assessed by peak systolic velocity (PSV), end-diastolic velocity (EDV) and resistivity index (RI) assessed by Doppler examination; From up to 30 days before Baseline, Baseline, 30 days, 60 days
Secondary Adverse effects report Adverse effects evaluation of compound use and application Baseline 30 days, 60 days and 75 days
Secondary Physical examination of the applied region Number of participants with abnormal physical exam findings in the applied region From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days
Secondary Change in SBP Change in Systolic Blood Pressure From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days
Secondary Change in DBP Change in Diastolic Blood Pressure From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days
Secondary Change in Heart Rate (HR) Change in Heart Rate From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days
Secondary Basal chest electrocardiogram (ECG). Number of participants with abnormal ECG test results From up to 30 days before Baseline, 30 days and 60 days
Secondary Blood evaluation Number of participants with abnormal laboratory test results From up to 30 days before Baseline, and 60 days
Secondary Urine evaluation Number of participants with abnormal laboratory test results From up to 30 days before Baseline, and 60 days
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A